{
  "ticker": "RHY",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02961334",
  "id": "02961334",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250624",
  "time": "0916",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250624/pdf/06l1d2pskm9glh.pdf",
  "summary": "- **NATA Accreditation Reinstated**: Full reinstatement of NATA accreditation for geneType\u2122 cancer risk assessment portfolio, completing laboratory integration post-acquisition.  \n- **ColoSTAT\u00ae Commercialization Progress**: Accreditation is a key step toward launching ColoSTAT\u00ae as an in-house IVD, pending variation assessment. Enables clinical deployment and real-world data generation.  \n\n*No capital markets or trading-specific material information identified.*",
  "usage": {
    "prompt_tokens": 1288,
    "completion_tokens": 88,
    "total_tokens": 1376,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-23T23:30:23.669621"
}